Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report first-quarter results on May 2, 2024.Once a rock-solid biotech stock to invest in, Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine.  These challenges are likely to have negatively impacted the upcoming results.The Zacks Consensus Estimate for REGN’s first-quarter revenues is pegged at $3.2 billion, while the same for earnings is pinned at $10.20 per share.Decline in Eylea SalesA sig ...